VSTM: Bull Flag detected on 17 Jul 2026

Verastem is forming a bull flag pattern as the stock consolidates after a strong 2-week rally of 40.73% and 1-month gain of 44.25%, following recent commercial progress with AVMAPKI FAKZYNJA CO-PACK, which generated $18.7 million in Q1 2026 revenue. At $5.77, the stock sits near resistance at $5.57 with key support at $5.10. The pattern scores 80 overall (pattern quality: 37/40, structure 15/15, breakout 10/13, volume 12/12), reflecting strong structural integrity. However, volume is below average at 0.61x relative volume, and RSI reads 72.34—overbought territory—suggesting caution on breakout confirmation. The conservative target sits at $5.96, requiring only 3.3% upside.

VSTM achieved FDA approval in May 2025 for AVMAPKI FAKZYNJA CO-PACK as the first treatment specifically approved for KRAS-mutated recurrent low-grade serous ovarian cancer. The company initiated Phase 2 registration-directed trials for VS-7375, an oral KRAS G12D inhibitor, with early data expected in H1 2026 and mature data in H2 2026. Q1 2026 earnings released May 7 showed -$0.37 EPS, beating consensus of -$0.465, signaling better-than-expected burn management. Wall Street consensus is Strong Buy with 5 analysts rating VSTM and a $14.20 price target. Cash runway extends into H1 2027 with $181.7 million in liquid resources. The sector regime is bullish, supporting biotech sentiment.

A successful breakout above $5.57 resistance would complete the bull flag and target the conservative measure of $5.96 (3.3% upside), with potential extension toward $6.30 based on prior swing highs. The breakout requires volume confirmation—current volume is weak at 61% of 20-day average, so a breakout should appear on above-average volume to validate conviction. The win probability of 73.85% reflects favorable historical precedent for this pattern type. Invalidation occurs on a close below $5.10, which represents the flag's lower boundary and would suggest consolidation failure.

CEO Dan Paterson sold 20,871 shares on June 22, 2026, as part of a pattern of insider selling (66,382 shares sold over the past year with no purchases). RSI at 72.34 signals overbought conditions, increasing pullback risk in the near term. After the May 7 earnings beat, the stock fell 13.6%, indicating profit-taking despite positive results. Analyst concerns note that VS-7375 data lags competitors' KRAS inhibitors in comparable indications, creating pipeline execution risk. The company faces limited cash reserves and stiff competitive pressure. Volume has declined 39% below average, a warning sign of weakening participation. Market regime is bearish (-0.3 score), conflicting with sector bullishness. Next major catalyst is H2 2026 mature VS-7375 data.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.